301. Macular dystrophy Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 46 / Drugs : 42 - (DrugBank : 11) / Drug target genes : 9 - Drug target pathways : 67
Macular dystrophy and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
| ID | Diseases (Sorted by score) | Score |
|---|---|---|
| 301 | Macular dystrophy | - |
| 299 | Cystic fibrosis | 2.894 |
| 77 | Growth hormone secreting pituitary adenoma | 2.000 |
| 65 | Primary immunodeficiency | 1.877 |
| 85 | Idiopathic interstitial pneumonia | 1.868 |
| 86 | Pulmonary arterial hypertension | 1.867 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 1.811 |
| 265 | Lipodystrophy | 1.231 |
| 225 | Congenital nephrogenic diabetes insipidus | 1.200 |
| 113 | Muscular dystrophy | 1.102 |
| 75 | Cushing disease | 1.097 |
| 49 | Systemic lupus erythematosus | 1.053 |
| 97 | Ulcerative colitis | 1.042 |
| 2 | Amyotrophic lateral sclerosis | 1.035 |
| 46 | Malignant rheumatoid arthritis | 1.032 |
| 6 | Parkinson disease | 1.032 |